Literature DB >> 6875817

5-Fluorouracil concentrations in rat plasma, parotid saliva, and bile and protein binding in rat plasma.

L A Celio, G J DiGregorio, E Ruch, J N Pace, A J Piraino.   

Abstract

The pharmacokinetics of 5-fluorouracil were studied over a 60-min period in rats that received 12.5, 25.0, and 50.0 mg/kg iv. The plasma concentration-time relationship and the detectability in bile and parotid saliva (a route of elimination heretofore given little or no attention) were examined. Protein binding of 5-fluorouracil at concentrations chosen to approximate those found in plasma was determined by equilibrium dialysis. Bile-plasma and parotid saliva-plasma concentration ratios were calculated. 5-Fluorouracil concentrations were quantitated by high-performance liquid chromatography. Plasma concentrations at all doses studied appeared to rapidly decline. The half-life, however, at the 50.0-mg/kg dose (27 min) was significantly longer (p less than 0.025) than the corresponding half-life at the 25.0-mg/kg dose (22 min). This may be attributed to an easily saturable hepatic degradation. Although an observed decline in bile-plasma and parotid saliva-plasma concentration ratios at higher doses may represent saturation of these excretary routes, the small amounts of 5-fluorouracil detected in bile and parotid saliva probably contribute negligibly to the elimination of the total drug equivalents administered. Parotid saliva-plasma concentration ratios were not useful in predicting plasma protein binding as determined by equilibrium dialysis. Excretion of intravenously administered 5-fluorouracil in saliva, however, exposes the upper GI tract to this agent and may play a part in causing stomatitis in patients receiving the drug by this route.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6875817     DOI: 10.1002/jps.2600720605

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

1.  Resveratrol synergistically augments anti-tumor effect of 5-FU in vitro and in vivo by increasing S-phase arrest and tumor apoptosis.

Authors:  Jiening Dun; Xueyan Chen; Haixia Gao; Yan Zhang; Huajun Zhang; Yongjian Zhang
Journal:  Exp Biol Med (Maywood)       Date:  2015-03-02

2.  Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model.

Authors:  Lena E Friberg; Marie Sandström; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2009-08-27       Impact factor: 3.850

3.  Transpapillary drug delivery to the breast.

Authors:  Kaushalkumar Dave; Ranjith Averineni; Preety Sahdev; Omathanu Perumal
Journal:  PLoS One       Date:  2014-12-29       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.